Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
STU:LSI's EV-to-FCF is ranked worse than 81.95% of 349
companies
in the Biotechnology industry
Industry Median: 14.07
vs STU:LSI: 61.85
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CK Life Sciences International Holdings (STU:LSI) EV-to-FCF Explanation
EV-to-FCF is a valuation multiple that allows analysts and investors to compare stocks, preferably in the same sector or industry. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio (TTM) to determine the fair market value of a company.
CK Life Sciences International Holdings's PE Ratio (TTM) for today is calculated as:
CK Life Sciences International Holdings's share price for today is €0.061.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CK Life Sciences International Holdings's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Dec. 2025 was €-0.002.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Enterprise Value is used because it is a more complete measure in reflecting how much an investor pays when buying a company. Free Cash Flow is an important financial metric because it represents the actual amount of cash at a company's disposal. Companies with a low EV-to-FCF ratio, combined with a strong balance sheet are generally considered as undervalued.
CK Life Sciences International Holdings EV-to-FCF Related Terms
CK Life Sciences International Holdings EV-to-FCF Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CK Life Sciences International Holdings EV-to-FCF Chart
CK Life Sciences International Holdings Annual Data
For the Biotechnology subindustry, CK Life Sciences International Holdings's EV-to-FCF, along with its competitors' market caps and EV-to-FCF data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CK Life Sciences International Holdings EV-to-FCF vs Biotechnology Industry
CK Life Sciences International Holdings's current Enterprise Value is €1,268.9 Mil.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. CK Life Sciences International Holdings's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was €20.5 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CK Life Sciences International Holdings (STU:LSI) has a EV-to-FCF of 61.85 as of Aug. 02, 2026. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on CK Life Sciences International Holdings and its competitors. This is 16% below median its historical median of 73.47. According to the industry distribution chart, CK Life Sciences International Holdings ranks #286 out of 349 companies in the Biotechnology industry, placing it in the top 81.9%.
Is CK Life Sciences International Holdings' EV-to-FCF too high?
CK Life Sciences International Holdings' current EV-to-FCF of 61.85 is 16% below median its 10-year median of 73.47. The Biotechnology industry median EV-to-FCF is 14.07. CK Life Sciences International Holdings' value of 61.85 is 339.6% above this industry median. Based on the distribution chart, CK Life Sciences International Holdings ranks #286 out of 349 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, CK Life Sciences International Holdings has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does CK Life Sciences International Holdings' EV-to-FCF compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, CK Life Sciences International Holdings ranks #286 out of 349 companies for EV-to-FCF. This places CK Life Sciences International Holdings in the lower half of its industry. The industry median EV-to-FCF is 14.07. CK Life Sciences International Holdings' value of 61.85 is 339.6% above this benchmark. While the company's 10-year median is 73.47 vs. the industry median of 14.07, CK Life Sciences International Holdings has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-FCF for a Biotechnology company?
The median EV-to-FCF among Biotechnology companies is 14.07, based on 349 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-FCF significantly above this median, while those in the bottom quartile fall well below. However, EV-to-FCF should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CK Life Sciences International Holdings's current EV-to-FCF of 61.85 is 339.6% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-FCF mean?
A high EV-to-FCF can signal that a stock is expensive relative to its fundamentals. EV to FCF ratio is the company's enterprise value divided by free cash flow. View historical data on CK Life Sciences International Holdings and its competitors. For the Biotechnology industry, the median EV-to-FCF is 14.07 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CK Life Sciences International Holdings's current EV-to-FCF is 61.85, which is 16% below median its own 10-year median of 73.47. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CK Life Sciences International Holdings stock overvalued right now?
CK Life Sciences International Holdings (STU:LSI) has a current EV-to-FCF of 61.85. The stock's GF Value™ is €0.08, compared to a current price of €0.06 — trading 23.8% below its estimated fair value. The current EV-to-FCF is 61.85, which is 16% below median its 10-year median of 73.47 and 339.6% above the Biotechnology industry median of 14.07. CK Life Sciences International Holdings' overall GF Score™ is 34/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-FCF calculated?
EV-to-FCF is calculated from a company's financial statements. For CK Life Sciences International Holdings (STU:LSI), the current EV-to-FCF is 61.85 as of Aug. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CK Life Sciences International Holdings (STU:LSI) Overvalued in 2026?
Based on GuruFocus' analysis, CK Life Sciences International Holdings stock appears to be undervalued.
The current stock price of €0.06 is trading 23.8% below its estimated GF Value™ of €0.08.
Key valuation signals for STU:LSI:
EV-to-FCF: 61.85 (16% below median its 10-year median of 73.47)
GF Value™: €0.08 vs. price of €0.06 (23.8% below fair value)
Industry Position: 339.6% above the Biotechnology median (#286 of 349)
No single metric tells the full story. See the STU:LSI stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CK Life Sciences International Holdings Inc is an international life sciences company. It is engaged in research and development, manufacturing, commercialization, marketing and selling of health and agriculture-related products, as well as investment in a portfolio of vineyards, and various financial and investment products. Its pipeline includes Seviprotimut-L, TTX-MC138, Seviprotimut-L + TTX-MC138, TTX-RIGA, Halneuron, among others. Its segments include Agriculture-related, Nutraceutical, and Pharmaceuticals & Diagnostics R&D with the majority of the revenue deriving from Nutraceutical segment. Geographically it operates in Asia Pacific that derives the majority of the revenue and North America.
34GF Score
Get the complete analysis for STU:LSI
EV-to-FCF is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:LSI has been successfully added to your 
